Gadavist

Active Ingredient(s): Gadobutrol
FDA Approved: * March 14, 2011
Pharm Company: * BAYER HEALTHCARE PHARMS
Category: Diagnostic Aid

Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and the United States.[1][2][3][4] As of 2007, it was the only GBCA approved at 1.0 molar concentrations.[5] Gadobutrol is marketed by Bayer AG as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.[6] In India, it is also marketed by Vivere Imaging as Viv-butrol.&a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Gadavist 604.72 mg/ml Intravenous Injection

NDC: 50419-325

Labeler:

Bayer Healthcare Pharmaceuticals Inc.